{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:47:25Z","timestamp":1793141245919,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Intraductal carcinoma of the prostate (IDC-P) is a histological subtype that differs from conventional acinar adenocarcinoma in terms of its origin, appearance, and pathological features. For IDC-P, there is currently no recognized best course of action, and its prognosis is unclear. The goal of this study is to analyze independent prognostic factors in IDC-P patients and to develop and validate a nomogram to predict overall survival (OS) and cancer-specific survival (CSS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical data for IDC-P patients were collected from the Surveillance, Epidemiology, and End Results database. To identify the independent variables influencing prognosis, multivariate Cox regression analysis was performed. A nomogram model was created utilizing these variables after comparing the variations in OS and CSS among various subgroups using Kaplan\u2012Meier curves. Internal validation of the nomograms was verified using the bootstrap resampling method.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study included 280 IDC-P patients in total. Marital status, summary stage, grade, and the presence of lung metastases were significant factors impacting OS, and CSS was significantly influenced by marital status, summary stage, AJCC stage, the presence of lung metastases, the presence of bone metastases, and PSA according to univariate and multivariate Cox regression models (<jats:italic>P\u2009&lt;\u2009<\/jats:italic>0.05). Nomogram models were created to estimate OS and CSS using these parameters. The OS prediction model\u2019s C-index was 0.744, whereas the CSS prediction model\u2019s C-index was 0.831.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We developed and verified nomogram models for the prediction of 1-, 3-, and 5-year OS and CSS in patients with IDC-P. These nomograms serve as a resource for evaluating patient prognosis, therapy, and diagnosis, ultimately improving clinical decision-making accuracy.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-023-05582-5","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T13:02:06Z","timestamp":1706446926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Nomogram for predicting the overall survival and cancer-specific survival of patients with intraductal carcinoma of the prostate"],"prefix":"10.1007","volume":"150","author":[{"given":"Yongqiang","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingqi","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongxiang","family":"Diao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,28]]},"reference":[{"issue":"7","key":"5582_CR1","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1111\/cas.15392","volume":"113","author":"R Aizawa","year":"2022","unstructured":"Aizawa R, Tsuzuki T, Haga H, Nakamura K, Ogata T, Inoue T, Kobayashi T, Akamatsu S, Goto T, Ogawa O, Mizowaki T (2022) Clinical significance of IDC-P as predictive factor after intensity-modulated radiation therapy. Cancer Sci 113(7):2425\u20132433. https:\/\/doi.org\/10.1111\/cas.15392","journal-title":"Cancer Sci"},{"issue":"4","key":"5582_CR2","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1016\/S1470-2045(14)71116-7","volume":"16","author":"VP Balachandran","year":"2015","unstructured":"Balachandran VP, Gonen M, Smith JJ, DeMatteo RP (2015) Nomograms in oncology: more than meets the eye. Lancet Oncol 16(4):e173\u2013e180. https:\/\/doi.org\/10.1016\/S1470-2045(14)71116-7","journal-title":"Lancet Oncol"},{"issue":"3","key":"5582_CR3","first-page":"207","volume":"96","author":"HR Bates Jr","year":"1973","unstructured":"Bates HR Jr, Thornton JL (1973) Adenocarcinomas of primary prostatic ducts and utricle. Arch Pathol 96(3):207","journal-title":"Arch Pathol"},{"issue":"1","key":"5582_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1002\/(sici)1097-0045(20000401)43:1<11::aid-pros3>3.0.co;2-b","volume":"43","author":"RJ Cohen","year":"2000","unstructured":"Cohen RJ, McNeal JE, Baillie T (2000) Patterns of differentiation and proliferation in intraductal carcinoma of the prostate: significance for cancer progression. Prostate 43(1):11\u201319. https:\/\/doi.org\/10.1002\/(sici)1097-0045(20000401)43:1%3c11::aid-pros3%3e3.0.co;2-b","journal-title":"Prostate"},{"issue":"9","key":"5582_CR5","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-021-01090-2","volume":"23","author":"B Considine","year":"2021","unstructured":"Considine B, Adeniran A, Hurwitz ME (2021) Current understanding and management of intraductal carcinoma of the prostate. Curr Oncol Rep 23(9):110. https:\/\/doi.org\/10.1007\/s11912-021-01090-2","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"5582_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A (2020) Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol 77(1):38\u201352. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.005","journal-title":"Eur Urol"},{"issue":"5","key":"5582_CR7","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.3349\/ymj.2016.57.5.1054","volume":"57","author":"MK Divatia","year":"2016","unstructured":"Divatia MK, Ro JY (2016) Intraductal carcinoma of the prostate gland: recent advances. Yonsei Med J 57(5):1054\u20131062. https:\/\/doi.org\/10.3349\/ymj.2016.57.5.1054","journal-title":"Yonsei Med J"},{"issue":"2","key":"5582_CR8","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/1097-0142(197308)32:2<402::aid-cncr2820320218>3.0.co;2-q","volume":"32","author":"VE Dube","year":"1973","unstructured":"Dube VE, Farrow GM, Greene LF (1973) Prostatic adenocarcinoma of ductal origin. Cancer 32(2):402\u2013409. https:\/\/doi.org\/10.1002\/1097-0142(197308)32:2%3c402::aid-cncr2820320218%3e3.0.co;2-q","journal-title":"Cancer"},{"issue":"6","key":"5582_CR9","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1016\/j.eururo.2009.10.020","volume":"57","author":"E Efstathiou","year":"2010","unstructured":"Efstathiou E, Abrahams NA, Tibbs RF, Wang X, Pettaway CA, Pisters LL, Mathew PF, Do KA, Logothetis CJ, Troncoso P (2010) Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. Eur Urol 57(6):1030\u20131038. https:\/\/doi.org\/10.1016\/j.eururo.2009.10.020","journal-title":"Eur Urol"},{"issue":"1","key":"5582_CR10","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40880-019-0411-7","volume":"39","author":"J Feng","year":"2019","unstructured":"Feng J, Polychronidis G, Heger U, Frongia G, Mehrabi A, Hoffmann K (2019) Incidence trends and survival prediction of hepatoblastoma in children: a population-based study. Cancer Commun (Lond, Engl) 39(1):62. https:\/\/doi.org\/10.1186\/s40880-019-0411-7","journal-title":"Cancer Commun (Lond, Engl)"},{"issue":"5","key":"5582_CR11","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1097\/PAS.0000000000001417","volume":"44","author":"JS Gandhi","year":"2020","unstructured":"Gandhi JS, Smith SC, Paner GP, McKenney JK, Sekhri R, Osunkoya AO, Baras AS, DeMarzo AM, Cheville JC, Jimenez RE, Trpkov K, Colecchia M, Ro JY, Montironi R, Menon S, Hes O, Williamson SR, Hirsch MS, Netto GJ, Fine SW, Amin MB (2020) Reporting practices and resource utilization in the era of intraductal carcinoma of the prostate: a survey of genitourinary subspecialists. Am J Surg Pathol 44(5):673\u2013680. https:\/\/doi.org\/10.1097\/PAS.0000000000001417","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"5582_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/s0022-5347(17)56763-4","volume":"121","author":"LF Greene","year":"1979","unstructured":"Greene LF, Farrow GM, Ravits JM, Tomera FM (1979) Prostatic adenocarcinoma of ductal origin. J Urol 121(3):303\u2013305. https:\/\/doi.org\/10.1016\/s0022-5347(17)56763-4","journal-title":"J Urol"},{"issue":"6","key":"5582_CR13","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1002\/pros.22786","volume":"74","author":"K Kimura","year":"2014","unstructured":"Kimura K, Tsuzuki T, Kato M, Saito AM, Sassa N, Ishida R, Hirabayashi H, Yoshino Y, Hattori R, Gotoh M (2014) Prognostic value of intraductal carcinoma of the prostate in radical prostatectomy specimens. Prostate 74(6):680\u2013687. https:\/\/doi.org\/10.1002\/pros.22786","journal-title":"Prostate"},{"issue":"533","key":"5582_CR14","doi-asserted-by":"publisher","first-page":"eaaz0152","DOI":"10.1126\/scitranslmed.aaz0152","volume":"12","author":"MG Lawrence","year":"2020","unstructured":"Lawrence MG, Porter LH, Clouston D, Murphy DG, Frydenberg M, Taylor RA, Risbridger GP (2020) Knowing what\u2019s growing: Why ductal and intraductal prostate cancer matter. Sci Transl Med 12(533):eaaz0152. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0152","journal-title":"Sci Transl Med"},{"key":"5582_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3503","volume":"371","author":"CG Mazariego","year":"2020","unstructured":"Mazariego CG, Egger S, King MT, Juraskova I, Woo H, Berry M, Armstrong BK, Smith DP (2020) Fifteen year quality of life outcomes in men with localised prostate cancer: population based Australian prospective study. BMJ (Clin Res Ed) 371:m3503. https:\/\/doi.org\/10.1136\/bmj.m3503","journal-title":"BMJ (Clin Res Ed)"},{"issue":"6","key":"5582_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/j.1464-410X.2011.10520.x","volume":"109","author":"JJ Meeks","year":"2012","unstructured":"Meeks JJ, Zhao LC, Cashy J, Kundu S (2012) Incidence and outcomes of ductal carcinoma of the prostate in the USA: analysis of data from the Surveillance, Epidemiology, and End Results program. BJU Int 109(6):831\u2013834. https:\/\/doi.org\/10.1111\/j.1464-410X.2011.10520.x","journal-title":"BJU Int"},{"issue":"1","key":"5582_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM (2016) The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours. Eur Urol 70(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029","journal-title":"Eur Urol"},{"issue":"6","key":"5582_CR18","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.juro.2010.08.017","volume":"184","author":"TM Morgan","year":"2010","unstructured":"Morgan TM, Welty CJ, Vakar-Lopez F, Lin DW, Wright JL (2010) Ductal adenocarcinoma of the prostate: increased mortality risk and decreased serum prostate specific antigen. J Urol 184(6):2303\u20132307. https:\/\/doi.org\/10.1016\/j.juro.2010.08.017","journal-title":"J Urol"},{"issue":"4","key":"5582_CR19","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1309\/AJCP8EL5FTZSOBIH","volume":"133","author":"C O'Brien","year":"2010","unstructured":"O\u2019Brien C, True LD, Higano CS, Rademacher BL, Garzotto M, Beer TM (2010) Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. Am J Clin Pathol 133(4):654\u2013661. https:\/\/doi.org\/10.1309\/AJCP8EL5FTZSOBIH","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"5582_CR20","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1464-410X.2010.09539.x","volume":"107","author":"BA O'Brien","year":"2011","unstructured":"O\u2019Brien BA, Cohen RJ, Wheeler TM, Moorin RE (2011) A post-radical-prostatectomy nomogram incorporating new pathological variables and interaction terms for improved prognosis. BJU Int 107(3):389\u2013395. https:\/\/doi.org\/10.1111\/j.1464-410X.2010.09539.x","journal-title":"BJU Int"},{"issue":"4","key":"5582_CR21","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.urolonc.2007.05.028","volume":"26","author":"E Orihuela","year":"2008","unstructured":"Orihuela E, Green JM (2008) Ductal prostate cancer: contemporary management and outcomes. Urol Oncol 26(4):368\u2013371. https:\/\/doi.org\/10.1016\/j.urolonc.2007.05.028","journal-title":"Urol Oncol"},{"issue":"4","key":"5582_CR22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.urology.2015.07.009","volume":"86","author":"VT Packiam","year":"2015","unstructured":"Packiam VT, Patel SG, Pariser JJ, Richards KA, Weiner AB, Paner GP, VanderWeele DJ, Zagaja GP, Eggener SE (2015) Contemporary population-based comparison of localized ductal adenocarcinoma and high-risk acinar adenocarcinoma of the prostate. Urology 86(4):777\u2013782. https:\/\/doi.org\/10.1016\/j.urology.2015.07.009","journal-title":"Urology"},{"issue":"4","key":"5582_CR23","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.eururo.2017.03.013","volume":"72","author":"LH Porter","year":"2017","unstructured":"Porter LH, Lawrence MG, Ilic D, Clouston D, Bolton DM, Frydenberg M, Murphy DG, Pezaro C, Risbridger GP, Taylor RA (2017) Systematic review links the prevalence of intraductal carcinoma of the prostate to prostate cancer risk categories. Eur Urol 72(4):492\u2013495. https:\/\/doi.org\/10.1016\/j.eururo.2017.03.013","journal-title":"Eur Urol"},{"issue":"6","key":"5582_CR24","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1111\/bju.14043","volume":"121","author":"LH Porter","year":"2018","unstructured":"Porter LH, Hashimoto K, Lawrence MG, Pezaro C, Clouston D, Wang H, Papargiris M, Thorne H, Li J, kConFab, Ryan A, Norden S, Moon D, Bolton DM, Sengupta S, Frydenberg M, Murphy DG, Risbridger GP, Taylor RA (2018) Intraductal carcinoma of the prostate can evade androgen deprivation, with emergence of castrate-tolerant cells. BJU Int 121(6):971\u2013978. https:\/\/doi.org\/10.1111\/bju.14043","journal-title":"BJU Int"},{"issue":"1","key":"5582_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/bco2.60","volume":"2","author":"N Ranasinha","year":"2021","unstructured":"Ranasinha N, Omer A, Philippou Y, Harriss E, Davies L, Chow K, Chetta PM, Erickson A, Rajakumar T, Mills IG, Bryant RJ, Hamdy FC, Murphy DG, Loda M, Hovens CM, Corcoran NM, Verrill C, Lamb AD (2021) Ductal adenocarcinoma of the prostate: A systematic review and meta-analysis of incidence, presentation, prognosis, and management. BJUI Compass 2(1):13\u201323. https:\/\/doi.org\/10.1002\/bco2.60","journal-title":"BJUI Compass"},{"issue":"4","key":"5582_CR26","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1016\/j.juro.2010.06.017","volume":"184","author":"BD Robinson","year":"2010","unstructured":"Robinson BD, Epstein JI (2010) Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. J Urol 184(4):1328\u20131333. https:\/\/doi.org\/10.1016\/j.juro.2010.06.017","journal-title":"J Urol"},{"issue":"7","key":"5582_CR27","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1097\/00000478-199807000-00006","volume":"22","author":"MA Rubin","year":"1998","unstructured":"Rubin MA, de La Taille A, Bagiella E, Olsson CA, O\u2019Toole KM (1998) Cribriform carcinoma of the prostate and cribriform prostatic intraepithelial neoplasia: incidence and clinical implications. Am J Surg Pathol 22(7):840\u2013848. https:\/\/doi.org\/10.1097\/00000478-199807000-00006","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"5582_CR28","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.humpath.2009.08.010","volume":"41","author":"H Samaratunga","year":"2010","unstructured":"Samaratunga H, Duffy D, Yaxley J, Delahunt B (2010) Any proportion of ductal adenocarcinoma in radical prostatectomy specimens predicts extraprostatic extension. Hum Pathol 41(2):281\u2013285. https:\/\/doi.org\/10.1016\/j.humpath.2009.08.010","journal-title":"Hum Pathol"},{"issue":"2","key":"5582_CR29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.pathol.2019.11.001","volume":"52","author":"H Samaratunga","year":"2020","unstructured":"Samaratunga H, Delahunt B, Egevad L, Srigley JR, Billis A, Bostwick DG, Camparo P, Cheng L, Clouston D, Denham J, Furusato B, Hartmann A, Jufe L, Kench J, Kenwright DN, Kristiansen G, Leite KRM, MacLennan GT, Merrimen J, Moch H, Varma M (2020) Intraductal carcinoma of the prostate is an aggressive form of invasive carcinoma and should be graded. Pathology 52(2):192\u2013196. https:\/\/doi.org\/10.1016\/j.pathol.2019.11.001","journal-title":"Pathology"},{"issue":"3","key":"5582_CR30","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"Cancer J Clin"},{"issue":"4","key":"5582_CR31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/j.1442-2042.2010.02460.x","volume":"17","author":"H Suzuki","year":"2010","unstructured":"Suzuki H, Hinotsu S, Akaza H, Fujii Y, Kawakami S, Kihara K, Akakura K, Suzuki M, Kitamura T, Homma Y, Mizokami A (2010) Hormonal therapy for prostate cancer: current topics and future perspectives. Int J Urol 17(4):302\u2013313. https:\/\/doi.org\/10.1111\/j.1442-2042.2010.02460.x","journal-title":"Int J Urol"},{"issue":"1","key":"5582_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.32074\/1591-951X-5-20","volume":"112","author":"E Szentirmai","year":"2020","unstructured":"Szentirmai E, Giannico GA (2020) Intraductal carcinoma of the prostate. Pathologica 112(1):17\u201324. https:\/\/doi.org\/10.32074\/1591-951X-5-20","journal-title":"Pathologica"},{"issue":"4","key":"5582_CR33","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1097\/JU.0000000000000316","volume":"202","author":"MC Tom","year":"2019","unstructured":"Tom MC, Nguyen JK, Lucian\u00f2 R, Mian OY, Stephans KL, Ciezki JP, Smile TD, Wei W, McKenney JK, Magi-Galluzzi C, Tendulkar RD (2019) Impact of cribriform pattern and intraductal carcinoma on gleason 7 prostate cancer treated with external beam radiotherapy. J Urol 202(4):710\u2013716. https:\/\/doi.org\/10.1097\/JU.0000000000000316","journal-title":"J Urol"},{"issue":"1","key":"5582_CR34","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/1055-9965.EPI-15-0578","volume":"25","author":"LA Torre","year":"2016","unstructured":"Torre LA, Siegel RL, Ward EM, Jemal A (2016) Global cancer incidence and mortality rates and trends\u2013an update. Cancer Epidemiol Biomarkers Prev 25(1):16\u201327. https:\/\/doi.org\/10.1158\/1055-9965.EPI-15-0578","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"5582_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s13014-019-1267-3","volume":"14","author":"VQ Trinh","year":"2019","unstructured":"Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, Taussky D, Trudel D (2019) Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiat Oncol (Lond, Engl) 14(1):60. https:\/\/doi.org\/10.1186\/s13014-019-1267-3","journal-title":"Radiat Oncol (Lond, Engl)"},{"issue":"9","key":"5582_CR36","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.ejca.2012.02.003","volume":"48","author":"T Van der Kwast","year":"2012","unstructured":"Van der Kwast T, Al Daoud N, Collette L, Sykes J, Thoms J, Milosevic M, Bristow RG, Van Tienhoven G, Warde P, Mirimanoff RO, Bolla M (2012) Biopsy diagnosis of intraductal carcinoma is prognostic in intermediate and high risk prostate cancer patients treated by radiotherapy. Eur J Cancer (Oxf, Engl) 48(9):1318\u20131325. https:\/\/doi.org\/10.1016\/j.ejca.2012.02.003","journal-title":"Eur J Cancer (Oxf, Engl)"},{"issue":"10","key":"5582_CR37","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/s0046-8177(98)90423-3","volume":"29","author":"G Wilcox","year":"1998","unstructured":"Wilcox G, Soh S, Chakraborty S, Scardino PT, Wheeler TM (1998) Patterns of high-grade prostatic intraepithelial neoplasia associated with clinically aggressive prostate cancer. Hum Pathol 29(10):1119\u20131123. https:\/\/doi.org\/10.1016\/s0046-8177(98)90423-3","journal-title":"Hum Pathol"},{"issue":"17","key":"5582_CR38","doi-asserted-by":"publisher","first-page":"29048","DOI":"10.18632\/oncotarget.16070","volume":"8","author":"YP Wu","year":"2017","unstructured":"Wu YP, Chen SH, Wang ST, Li XD, Cai H, Lin YZ, Xue XY, Wei Y, Zheng QS, Xu N (2017) Prognostic values of clinicopathological characteristics and survival outcomes in prostate infiltrating ductal carcinoma: a population-based study. Oncotarget 8(17):29048\u201329055. https:\/\/doi.org\/10.18632\/oncotarget.16070","journal-title":"Oncotarget"},{"issue":"S1","key":"5582_CR39","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1038\/modpathol.2017.138","volume":"31","author":"M Zhou","year":"2018","unstructured":"Zhou M (2018) High-grade prostatic intraepithelial neoplasia, PIN-like carcinoma, ductal carcinoma, and intraductal carcinoma of the prostate. Mod Pathol 31(S1):S71\u2013S79. https:\/\/doi.org\/10.1038\/modpathol.2017.138","journal-title":"Mod Pathol"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-05582-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-05582-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T13:05:23Z","timestamp":1711112723000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-05582-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["5582"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-05582-5","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]},"assertion":[{"value":"9 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors assert no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"45"}}